NCT02718911 2023-10-16
A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors
Eli Lilly and Company
Phase 1 Completed
Clinical Trials
4 trialsNCT03089645 2020-07-27
MEDI5083 Alone and in Combination With Durvalumab, Tremelimumab, and/or Docetaxel.
MedImmune LLC
Phase 1 Completed
NCT02261220 2020-03-06
A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors
MedImmune LLC
Phase 1 Completed
NCT02141347 2018-12-12
Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma
AstraZeneca
Phase 1 Completed